Skip to content

OS Therapies OSTX Current ratio

Current ratio at other companies

Immunome logo
ImmunomeIMNM
21.7×+11.2×
CTO
Citius Oncology, Inc.CTOR
0.5×+0.1×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.7×+4.4×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×

Where this comes from

Calculated from OS Therapies’s reported figures.

Based on the most recent quarter.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's current ratio?
OS Therapies (OSTX) reported current ratio of 0.1× in Q1 2026.
How has OS Therapies's current ratio changed year-over-year?
OS Therapies's current ratio decreased by 95.3% year-over-year, from 1.2× to 0.1×.
What is the long-term trend for OS Therapies's current ratio?
Over 2 years (2023 to 2025), OS Therapies's current ratio has grown at a -6.0% compound annual growth rate (CAGR), from 0× to 0×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.